Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 66 publications
Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank.
Journal: Urologic oncology
Published: May 12, 2025
Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study.
Journal: The Lancet. Oncology
Published: October 08, 2024
Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting.
Journal: Urologic oncology
Published: July 30, 2024
Oral Hypoxia-Inducible Factor 2α Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease: Subgroup Analysis of the Single-Arm Phase 2 LITESPARK-004 Study.
Journal: Ophthalmology
Published: January 18, 2024
Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study.
Journal: The Lancet. Oncology
Published: December 18, 2023
Unraveling the complexity of bladder-centric chronic pain by intravesical contrast enhanced MRI.
Journal: Continence (Amsterdam, Netherlands)
Published: September 01, 2023
PROBING THE INTERPLAY OF PERFUSION AND PERMEABILITY IN BLADDER INFLAMMATION.
Journal: Continence (Amsterdam, Netherlands)
Published: September 01, 2023
Last Updated: 09/26/2026